James Kim is an associate in the San Francisco office of Wilson Sonsini Goodrich & Rosati, where he practices corporate and securities law. He advises companies on general corporate matters, including formation and operation, corporate governance, debt and equity financings, mergers and acquisitions, and securities-related matters.
During law school, James worked as an extern for Justice Nathan D. Mihara of the California Court of Appeal for the Sixth District on a wide variety of civil and criminal appeals.
Prior to joining the firm, James practiced corporate law at Goodwin Procter LLP.
James Kim is an associate in the San Francisco office of Wilson Sonsini Goodrich & Rosati, where he practices corporate and securities law. He advises companies on general corporate matters, including formation and operation, corporate governance, debt and equity financings, mergers and acquisitions, and securities-related matters.
During law school, James worked as an extern for Justice Nathan D. Mihara of the California Court of Appeal for the Sixth District on a wide variety of civil and criminal appeals.
Prior to joining the firm, James practiced corporate law at Goodwin Procter LLP.
- J.D., Santa Clara University School of Law
- M.B.A., Santa Clara University, Leavey School of Business
- B.A., Legal Studies, University of California, Berkeley
- State Bar of California
- J.D., Santa Clara University School of Law
- M.B.A., Santa Clara University, Leavey School of Business
- B.A., Legal Studies, University of California, Berkeley
- State Bar of California
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
The Junevity RESET platform is based on exclusively licensed research by co-founder Dr. Janine Sengstack at the University of California at San Francisco. RESET uses large-scale human data and AI to identify genes—or transcription factors—that can regulate cell damage. Then, it develops siRNA therapeutics against these targets to return cells to health. Junevity will use this seed funding to enhance the RESET platform and develop its first therapeutic candidates in Type 2 diabetes, obesity, and frailty.
The Wilson Sonsini team that advised Junevity on the transaction included James Huie and James Kim.
For more information, please see Junevity’s news release.
- Privacy Policy
- Terms of Use
- Accessibility